DDInter157 DDInter927
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Azithromycin {u} (Compound) resembles {v} (Compound) Telithromycin
Azithromycin {u} (Compound) resembles {v} (Compound) Dirithromycin
Azithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Azithromycin {u} (Compound) binds {v} (Gene) CYP3A4
Azithromycin {u} (Compound) upregulates {v} (Gene) CDH3
Azithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Azithromycin {u} (Compound) downregulates {v} (Gene) TSTA3
Azithromycin {u} (Compound) causes {v} (Side Effect) Face oedema
Azithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Azithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Azithromycin (Compound) resembles Telithromycin (Compound)
Azithromycin (Compound) resembles Dirithromycin (Compound)
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Azithromycin (Compound) binds CYP3A4 (Gene)
Azithromycin (Compound) upregulates CDH3 (Gene)
Azithromycin (Compound) is included by Macrolides (Pharmacologic Class)
Azithromycin (Compound) downregulates TSTA3 (Gene)
Azithromycin (Compound) causes Face oedema (Side Effect)
Azithromycin may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli